Paromomycin
- Atc Codes:A07AA06
- CAS Codes:1263-89-4#7542-37-2
- PHARMGKB ID:1263-89-4#7542-37-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Humatin; Belgium: Gabbroral; Greece: Humatin; Germany: Humatin; Italy: Gabbroral, Humatin, Kaman; Luxembourg: Gabbroral; Spain: Humatin.
North America
Canada: Humatin; USA: Humatin (d), Paromomycin.
Drug combinations
Chemistry
Paromomycin Sulfate: C~23~H~45~N~5~O~14~ H~2~SO~4~. Mw: 615.63 (base). (1) D-Streptamine, O-2-amino-2-deoxy-α-D-glucopyranosyl-(1→4)-O-[O-2,6-diamino-2,6-dideoxy-β-L-idopyranosyl-(1→3)-β-D-ribofuranosyl-(1→5)]-2-deoxy-, sulfate; (2) O-2,6-Diamino-2,6-dideoxy-β-L-idopyranosyl-(1→3)-O-β-D-ribofuranosyl-(1→5)-O-[2-amino-2-deoxy-α-D-glucopyranosyl-(1→4)]-2-deoxystreptamine sulfate. CAS-1263-89-4; CAS-7542-37-2 (paromomycin).
Pharmacologic Category
Antibacterials; Aminoglycosides. Antiprotozoals; Amebicides. (ATC-Code: A07AA06).
Mechanism of action
Acts directly on ameba. Has antibacterial activity against normal and pathogenic organisms in GI tract. Interferes with bacterial protein synthesis by binding to 30 S ribosomal subunits.
Therapeutic use
Treatment of acute and chronic intestinal amebiasis. Hepatic coma.
Pregnancy and lactiation implications
As oral paromomycin is minimally absorbed from GI tract, may be drug of choice for treatment of amebiasis or giardiasis (unlabeled use) in pregnant women. Does not enter breast milk.
Unlabeled use
Treatment of cryptosporidiosis.
Contraindications
Hypersensitivity to paromomycin or any component of the formulation. Intestinal obstruction.
Warnings and precautions
Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment. Use with caution in possible or proven ulcerative bowel lesions.